Exhibit 99.2 Leronlimab (PRO 140) ® ® HIV - Cancer INVESTOR PRESENTATION January 2019 Professor Richard G. Pestell M.D., Ph.D., MB., B.S., F.A.C.P., F.R.A.C.P., F.A.A.A.S., M.B.A. Vice Chairman and Chief Medical Officer Nader Pourhassan Ph.D., President & CEO OTCQB: CYDY www.cytodyn.comExhibit 99.2 Leronlimab (PRO 140) ® ® HIV - Cancer INVESTOR PRESENTATION January 2019 Professor Richard G. Pestell M.D., Ph.D., MB., B.S., F.A.C.P., F.R.A.C.P., F.A.A.A.S., M.B.A. Vice Chairman and Chief Medical Officer Nader Pourhassan Ph.D., President & CEO OTCQB: CYDY www.cytodyn.com

Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding leronlimab’s efficacy in certain cancer indications, the predictive value or benefit from the Company’s prostate cancer prognostic test, the Company’s clinical focus, and the Company’s current and proposed trials. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company’s forward- looking statements are not guarantees of performance and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, the Company urges investors to specifically consider the various risk factors identified in the Company’s Form 10-K for the fiscal year ended May 31, 2018 in the section titled “Risk Factors” in Part I, Item 1A, and in our Form 10-Q for the quarterly period ended August 31, 2018 in the section titled “Risk Factors” in Part II, Item 1A, any of which could cause actual results to differ materially from those indicated by the Company’s forward-looking statements. The Company’s forward-looking statements reflect its current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. Investors should not place undue reliance on the Company’s forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of the Company’s cash position and the Company’s ongoing ability to raise additional capital to fund its operations, (ii) the Company’s ability to complete its Phase 2b/3 pivotal combination therapy trial for leronlimab (CD02) and to meet the FDA’s requirements with respect to safety and efficacy to support the filing of a Biologics License Application, (iii) the Company's ability to obtain FDA approval of PCaTest for use with prostate cancer patients; (iv)the Company’s ability to meet its debt obligations, if any, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) design, implementation and conduct of clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments for infection with HIV that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by the Company’s forward-looking statements. The Company intends that all forward-looking statements made in this presentation will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act of 1933, as amended, to the extent applicable. Except as required by law, the Company does not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this presentation. Additionally, the Company does not undertake any responsibility to update investors upon the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements. www.cytodyn.com 2 www.cytodyn.comForward-Looking Statements This presentation contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding leronlimab’s efficacy in certain cancer indications, the predictive value or benefit from the Company’s prostate cancer prognostic test, the Company’s clinical focus, and the Company’s current and proposed trials. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company’s forward- looking statements are not guarantees of performance and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, the Company urges investors to specifically consider the various risk factors identified in the Company’s Form 10-K for the fiscal year ended May 31, 2018 in the section titled “Risk Factors” in Part I, Item 1A, and in our Form 10-Q for the quarterly period ended August 31, 2018 in the section titled “Risk Factors” in Part II, Item 1A, any of which could cause actual results to differ materially from those indicated by the Company’s forward-looking statements. The Company’s forward-looking statements reflect its current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. Investors should not place undue reliance on the Company’s forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of the Company’s cash position and the Company’s ongoing ability to raise additional capital to fund its operations, (ii) the Company’s ability to complete its Phase 2b/3 pivotal combination therapy trial for leronlimab (CD02) and to meet the FDA’s requirements with respect to safety and efficacy to support the filing of a Biologics License Application, (iii) the Company's ability to obtain FDA approval of PCaTest for use with prostate cancer patients; (iv)the Company’s ability to meet its debt obligations, if any, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) design, implementation and conduct of clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments for infection with HIV that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by the Company’s forward-looking statements. The Company intends that all forward-looking statements made in this presentation will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act of 1933, as amended, to the extent applicable. Except as required by law, the Company does not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this presentation. Additionally, the Company does not undertake any responsibility to update investors upon the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements. www.cytodyn.com 2 www.cytodyn.com

Recent Developments • CD02 Phase 3, Pivotal trial - Combination Therapy • Achieved primary endpoint (p=0.0032) – 81% response rate – BLA in 1Q2019 • CD03 Phase 3 HIV investigative trial - 360+ enrolled (60 patients one year) • About 70% response rate at 525 mg - About 90% response rate at 700 mg • Phase 1b/2 in Triple Negative Breast Cancer • IND and Protocol has been accepted by the FDA and trial initiated • Encouraging preclinical data • Phase 2 Graft-versus-Host Disease (GvHD) • Received Orphan Drug Designation from FDA • Will have interim results in 1H 2019 (mouse model – GvHD eliminated) • Prognostic Test for Prostate Cancer • More accurate than current standard of care • Licensing agreement could be completed in 1H 2019 • Licensing and Partnering Discussions • Rights to leronlimab (PRO 140) China – France – Japan – USA are being explored www.cytodyn.com 3 3Recent Developments • CD02 Phase 3, Pivotal trial - Combination Therapy • Achieved primary endpoint (p=0.0032) – 81% response rate – BLA in 1Q2019 • CD03 Phase 3 HIV investigative trial - 360+ enrolled (60 patients one year) • About 70% response rate at 525 mg - About 90% response rate at 700 mg • Phase 1b/2 in Triple Negative Breast Cancer • IND and Protocol has been accepted by the FDA and trial initiated • Encouraging preclinical data • Phase 2 Graft-versus-Host Disease (GvHD) • Received Orphan Drug Designation from FDA • Will have interim results in 1H 2019 (mouse model – GvHD eliminated) • Prognostic Test for Prostate Cancer • More accurate than current standard of care • Licensing agreement could be completed in 1H 2019 • Licensing and Partnering Discussions • Rights to leronlimab (PRO 140) China – France – Japan – USA are being explored www.cytodyn.com 3 3

Leronlimab (PRO 140) – A Humanized Monoclonal Antibody Blocking HIV entry receptor (CCR5) Blocking CCR5/CCL5 interaction with leronlimab for use in CANCER Humanized monoclonal Binds to CCR5 co-receptor on antibody white blood cells HIV CD4 Leronlimab CCR5 Blocks HIV entry into white HAART blood cells T-Cell www.cytodyn.com 4 4Leronlimab (PRO 140) – A Humanized Monoclonal Antibody Blocking HIV entry receptor (CCR5) Blocking CCR5/CCL5 interaction with leronlimab for use in CANCER Humanized monoclonal Binds to CCR5 co-receptor on antibody white blood cells HIV CD4 Leronlimab CCR5 Blocks HIV entry into white HAART blood cells T-Cell www.cytodyn.com 4 4

FDA: “fast track designation” – “accelerated approval” NIH: $28 million grants BECAUSE Leronlimab HAART (PRO 140) No serious side effects and Ranges from mild to severe Side Effects no serious adverse events (SAEs) (Diarrhea, nausea, lethargy, in >670 patients in 8 clinical trials depression) Toxicity Problems with short- and Negligible toxicity long-term toxicity No drug resistance in patients 76% of HIV patients have Resistance on monotherapy for over 4 years at least one resistance Daily lifetime dosing with Weekly, easy, subcutaneous only 35% of patients with Compliance self administration complete viral load suppression www.cytodyn.com 5 5FDA: “fast track designation” – “accelerated approval” NIH: $28 million grants BECAUSE Leronlimab HAART (PRO 140) No serious side effects and Ranges from mild to severe Side Effects no serious adverse events (SAEs) (Diarrhea, nausea, lethargy, in >670 patients in 8 clinical trials depression) Toxicity Problems with short- and Negligible toxicity long-term toxicity No drug resistance in patients 76% of HIV patients have Resistance on monotherapy for over 4 years at least one resistance Daily lifetime dosing with Weekly, easy, subcutaneous only 35% of patients with Compliance self administration complete viral load suppression www.cytodyn.com 5 5

CD02 Pivotal Combination Trial with leronlimab (PRO 140) • 52 patients prescreened for R5 strain and failing current HAART regimen (3 class resistance or 2 class resistance with limited treatment options) • Primary efficacy endpoint: reduction in viral load after 1 week following single PRO 140 dose • All patients continue current HAART; 50% receive PRO 140 / 50% receive placebo p =0.0032 • PRO 140 patients achieved statistically significant reduction - • 24-week open-label with all patients on weekly PRO 140 with optimized HAART • 81% of patients completing trial achieved HIV viral load suppression of <50 cp/mL Recent approved drugs for this population range from 43% after 24 weeks to 45% after 48 weeks with vial load suppression of < 50 cp/mL • No reported SAEs related to PRO 140 – (670 patients with zero drug related SAE ) • 40 patients requested to continue PRO 140 in extension study • Regulatory path – expected first FDA approval for PRO 140 in combination therapy • Submission of rolling BLA with full BLA submission expected in 1H2019 • Safety data from 150 eligible patients from all CytoDyn HIV trials www.cytodyn.com 6 6CD02 Pivotal Combination Trial with leronlimab (PRO 140) • 52 patients prescreened for R5 strain and failing current HAART regimen (3 class resistance or 2 class resistance with limited treatment options) • Primary efficacy endpoint: reduction in viral load after 1 week following single PRO 140 dose • All patients continue current HAART; 50% receive PRO 140 / 50% receive placebo p =0.0032 • PRO 140 patients achieved statistically significant reduction - • 24-week open-label with all patients on weekly PRO 140 with optimized HAART • 81% of patients completing trial achieved HIV viral load suppression of <50 cp/mL Recent approved drugs for this population range from 43% after 24 weeks to 45% after 48 weeks with vial load suppression of < 50 cp/mL • No reported SAEs related to PRO 140 – (670 patients with zero drug related SAE ) • 40 patients requested to continue PRO 140 in extension study • Regulatory path – expected first FDA approval for PRO 140 in combination therapy • Submission of rolling BLA with full BLA submission expected in 1H2019 • Safety data from 150 eligible patients from all CytoDyn HIV trials www.cytodyn.com 6 6

Potential Approval for leronlimab (PRO 140) in HIV • Timeline for submitting rolling BLA • Non-Clinical - Completed • Clinical - 1Q19 • CMC (Manufacturing) - 1Q19 • Final Complete package: 1Q19 www.cytodyn.com 7 7Potential Approval for leronlimab (PRO 140) in HIV • Timeline for submitting rolling BLA • Non-Clinical - Completed • Clinical - 1Q19 • CMC (Manufacturing) - 1Q19 • Final Complete package: 1Q19 www.cytodyn.com 7 7

CD03 leronlimab (PRO 140) Investigative Monotherapy Trial • All patients prescreened for R5 strain with viral load suppression maintained with HAART • Ongoing open-label, 48-week trial with all patients receiving PRO 140 weekly injections • Investigative trial with focus on increasing responder rate and no harm to non-responders • Increasing response rate • With 525 mg - Responder rate of ~ 70% so far (4 to 12 months) • With 700 mg - Responder rate of ~ 90% so far (1 to ~4 months) • No reported SAEs related to leronlimab in any trial to date (over 670 patients) • Regulatory path • Conduct pivotal Phase 3 monotherapy trial • Submit leronlimab (PRO 140) for approval for label expansion as monotherapy, subject to approval as combination therapy www.cytodyn.com 8 8CD03 leronlimab (PRO 140) Investigative Monotherapy Trial • All patients prescreened for R5 strain with viral load suppression maintained with HAART • Ongoing open-label, 48-week trial with all patients receiving PRO 140 weekly injections • Investigative trial with focus on increasing responder rate and no harm to non-responders • Increasing response rate • With 525 mg - Responder rate of ~ 70% so far (4 to 12 months) • With 700 mg - Responder rate of ~ 90% so far (1 to ~4 months) • No reported SAEs related to leronlimab in any trial to date (over 670 patients) • Regulatory path • Conduct pivotal Phase 3 monotherapy trial • Submit leronlimab (PRO 140) for approval for label expansion as monotherapy, subject to approval as combination therapy www.cytodyn.com 8 8

U.S. Market Size for HIV Indication for leronlimab (PRO 140) Patients using Year HIV patients 1 resistance 2 resistance 3 resistance HAART 2017 1,373,636 712,532 645,646 218,248 28,372 2018 1,400,406 745,167 671,257 232,291 27,875 2019 1,421,563 775,245 694,404 246,842 27,153 2020 1,432,683 799,418 712,153 261,677 26,168 2021 1,450,405 827,477 733,273 276,750 24,907 2022 1,468,530 856,284 754,947 291,950 23,356 2023 1,487,096 885,878 777,208 307,164 21,501 2024 1,506,237 916,377 800,152 338,545 20,313 2025 1,514,925 940,855 817,758 354,548 17,727 Source: GlobalData & https://doi.org/10.1086/597352 www.cytodyn.com 9 9U.S. Market Size for HIV Indication for leronlimab (PRO 140) Patients using Year HIV patients 1 resistance 2 resistance 3 resistance HAART 2017 1,373,636 712,532 645,646 218,248 28,372 2018 1,400,406 745,167 671,257 232,291 27,875 2019 1,421,563 775,245 694,404 246,842 27,153 2020 1,432,683 799,418 712,153 261,677 26,168 2021 1,450,405 827,477 733,273 276,750 24,907 2022 1,468,530 856,284 754,947 291,950 23,356 2023 1,487,096 885,878 777,208 307,164 21,501 2024 1,506,237 916,377 800,152 338,545 20,313 2025 1,514,925 940,855 817,758 354,548 17,727 Source: GlobalData & https://doi.org/10.1086/597352 www.cytodyn.com 9 9

U.S. Market Potential for leronlimab (PRO 140) in HIV Alone Initial approval Combination Therapy • HAART failures: ~ 70,000* patients with 2 or more drug class resistances • 70,000 patients x 70% (R5-HIV strain) = 49,000 HIV patient R5 eligible • 49,000 patients x $24,000 (current market pricing) = ~ $1.2 billion • 49,000 patients x $75,000 (current market pricing) = ~ $3.7 billion Label Expansion Switch to Monotherapy Maintenance • Target population (suppressed viral load) = 17.5% of 1.3 million HIV+ = 227,500** • 227,500 patients x 70% (R5-HIV) = 159,250 patients • 159,250 patients x $24,000 (current market pricing) = ~ $3.8 billion • 159,250 patients x $75,000 (current market pricing) = ~ $12 billion * Market size – BioVid Market Research: 2 class resistance ~ 5% to 20% ~ 70,000 to 280,000 patients ** Market size – BioVid Market Research: Monotherapy ~ 60% to 100% suppressed viral load among ~ 480,000 to 770,000 www.cytodyn.com 1 10 0U.S. Market Potential for leronlimab (PRO 140) in HIV Alone Initial approval Combination Therapy • HAART failures: ~ 70,000* patients with 2 or more drug class resistances • 70,000 patients x 70% (R5-HIV strain) = 49,000 HIV patient R5 eligible • 49,000 patients x $24,000 (current market pricing) = ~ $1.2 billion • 49,000 patients x $75,000 (current market pricing) = ~ $3.7 billion Label Expansion Switch to Monotherapy Maintenance • Target population (suppressed viral load) = 17.5% of 1.3 million HIV+ = 227,500** • 227,500 patients x 70% (R5-HIV) = 159,250 patients • 159,250 patients x $24,000 (current market pricing) = ~ $3.8 billion • 159,250 patients x $75,000 (current market pricing) = ~ $12 billion * Market size – BioVid Market Research: 2 class resistance ~ 5% to 20% ~ 70,000 to 280,000 patients ** Market size – BioVid Market Research: Monotherapy ~ 60% to 100% suppressed viral load among ~ 480,000 to 770,000 www.cytodyn.com 1 10 0

U.S. Market Size - Research Report From BIOVID E Ex xe ec cu ut ti iv ve e S Su um mm ma ar ry y However, patients show a strong leronlimab (PRO 140) call to action • Monotherapy patients are slightly more likely to act Patient Reactions to PRO 140 (pre-video review) Monotherapy Patients Combo Therapy Patients upon their interest in PRO PRO 140 is a significant improvement vs. current options 55% 55% 140 by talking to their MD and/or searching for more Highly likely to start a conversation with my doctor 70% 60% product details on their own Highly likely to try to find more information about PRO 140 65% 60% • Both patient types see PRO Would schedule an appointment within 3 months to discuss PRO 140 70% 65% 140 as requiring minimal effort to implement in their Effort needed to make PRO 140 part of daily routine daily routine, and the majority do not have Very little/Moderate effort 85% 95% significant concerns with A lot of effort self-injecting PRO 140 10% 5% once/weekly long-term Way too much effort to take on 5% 0% 5% 15% 5% 10% Very concerned 25% 40% Level of concern about taking 60% PRO 140 as instructed Somewhat 40% concerned 5% 5% 15% 35% A little bit 35% concerned 35% Level of concern about taking Not concerned 45% PRO 140 long-term 25% 11 Base Size: Total Patients; Monotherapy Candidates (n=20); Combination Therapy Candidates (n=20) (OTCQB: CYDY) www.cytodyn.com www.cytodyn.com 1 11 1U.S. Market Size - Research Report From BIOVID E Ex xe ec cu ut ti iv ve e S Su um mm ma ar ry y However, patients show a strong leronlimab (PRO 140) call to action • Monotherapy patients are slightly more likely to act Patient Reactions to PRO 140 (pre-video review) Monotherapy Patients Combo Therapy Patients upon their interest in PRO PRO 140 is a significant improvement vs. current options 55% 55% 140 by talking to their MD and/or searching for more Highly likely to start a conversation with my doctor 70% 60% product details on their own Highly likely to try to find more information about PRO 140 65% 60% • Both patient types see PRO Would schedule an appointment within 3 months to discuss PRO 140 70% 65% 140 as requiring minimal effort to implement in their Effort needed to make PRO 140 part of daily routine daily routine, and the majority do not have Very little/Moderate effort 85% 95% significant concerns with A lot of effort self-injecting PRO 140 10% 5% once/weekly long-term Way too much effort to take on 5% 0% 5% 15% 5% 10% Very concerned 25% 40% Level of concern about taking 60% PRO 140 as instructed Somewhat 40% concerned 5% 5% 15% 35% A little bit 35% concerned 35% Level of concern about taking Not concerned 45% PRO 140 long-term 25% 11 Base Size: Total Patients; Monotherapy Candidates (n=20); Combination Therapy Candidates (n=20) (OTCQB: CYDY) www.cytodyn.com www.cytodyn.com 1 11 1

Leronlimab (PRO 140) Immunologic Indications Additional potential leronlimab (PRO 140) applications • GvHD • Cancer including tumor metastasis (Dr. Richard Pestell) www.cytodyn.com 1 12 2Leronlimab (PRO 140) Immunologic Indications Additional potential leronlimab (PRO 140) applications • GvHD • Cancer including tumor metastasis (Dr. Richard Pestell) www.cytodyn.com 1 12 2

Effect of leronlimab (PRO 140) on Xeno-GvHD Human BM Transplanted Into Immuno-Deficient Mice 100 24.0 23.5 80 Control Control 23.0 60 PRO 140 PRO 140 22.5 40 22.0 P < .01 P < .01 20 21.5 21.0 0 0 10 20 30 40 50 60 0 20 40 60 80 100 Day Day 13 www.cytodyn.com 1 13 3 Weight gm mean ± SE Survival %Effect of leronlimab (PRO 140) on Xeno-GvHD Human BM Transplanted Into Immuno-Deficient Mice 100 24.0 23.5 80 Control Control 23.0 60 PRO 140 PRO 140 22.5 40 22.0 P < .01 P < .01 20 21.5 21.0 0 0 10 20 30 40 50 60 0 20 40 60 80 100 Day Day 13 www.cytodyn.com 1 13 3 Weight gm mean ± SE Survival %

Expansion into Cancer Indications • Named world-renowned oncologist Dr. Richard Pestell Chief Medical Officer and Vice Chairman • Lead leronlimab (PRO 140) non-HIV development programs • Led 2 National Cancer Institute-designated cancer centers • Lombardi Comprehensive Cancer Center at Georgetown University • Sidney Kimmel Cancer Center at Thomas Jefferson University • Founded ProstaGene to develop CCR5 technology in cancer • Important focus on metastasis of many types of cancer • Research showed nearly 50% of 2,200 patients with breast cancer had overexpressed CCR5 • Published preclinical studies provide support • CCR5 inhibitors effectively blocked breast and colon cancer spread; blocked prostate cancer metastasis to bones and brain www.cytodyn.com 1 14 4Expansion into Cancer Indications • Named world-renowned oncologist Dr. Richard Pestell Chief Medical Officer and Vice Chairman • Lead leronlimab (PRO 140) non-HIV development programs • Led 2 National Cancer Institute-designated cancer centers • Lombardi Comprehensive Cancer Center at Georgetown University • Sidney Kimmel Cancer Center at Thomas Jefferson University • Founded ProstaGene to develop CCR5 technology in cancer • Important focus on metastasis of many types of cancer • Research showed nearly 50% of 2,200 patients with breast cancer had overexpressed CCR5 • Published preclinical studies provide support • CCR5 inhibitors effectively blocked breast and colon cancer spread; blocked prostate cancer metastasis to bones and brain www.cytodyn.com 1 14 4

CCR5 is Expressed in >50% of Breast Cancer – Metastatic cancer. Ø 50% of breast cancers CCR5+ Ø Leronlimab(PRO 140) reduces breast cancer invasion P<0.001 P<0.001 1000 800 600 400 200 0 Leronlimab Control PRO140 (1/500) Vicriviroc Professor Richard Pestell, PhD, MD www.cytodyn.com 1 15 5 Distance of Invasion (mm) Control PRO140 Vicriviroc CCL5CCR5 is Expressed in >50% of Breast Cancer – Metastatic cancer. Ø 50% of breast cancers CCR5+ Ø Leronlimab(PRO 140) reduces breast cancer invasion P<0.001 P<0.001 1000 800 600 400 200 0 Leronlimab Control PRO140 (1/500) Vicriviroc Professor Richard Pestell, PhD, MD www.cytodyn.com 1 15 5 Distance of Invasion (mm) Control PRO140 Vicriviroc CCL5

+2 Leronlimab (PRO 140) Blocks Breast Cancer Ca signaling A 20 sec before 60 sec after 240 sec after 60 sec after adding CCL5 adding CCL5 adding CCL5 adding FBS B C FBS 3 3 FBS CCL5 CCL5 2 2 1 1 0 0 Control PRO140 -1 -1 0 200 400 600 800 1000 0 200 400 600 800 1000 Time (Sec) Time (Sec) Professor Richard Pestell, PhD, MD www.cytodyn.com 1 16 6 PRO140 (1/100) Control Relative FI of Fluo-4 Relative FI of Fluo-4+2 Leronlimab (PRO 140) Blocks Breast Cancer Ca signaling A 20 sec before 60 sec after 240 sec after 60 sec after adding CCL5 adding CCL5 adding CCL5 adding FBS B C FBS 3 3 FBS CCL5 CCL5 2 2 1 1 0 0 Control PRO140 -1 -1 0 200 400 600 800 1000 0 200 400 600 800 1000 Time (Sec) Time (Sec) Professor Richard Pestell, PhD, MD www.cytodyn.com 1 16 6 PRO140 (1/100) Control Relative FI of Fluo-4 Relative FI of Fluo-4

CCR5 Antagonists Block Breast Cancer Metastasis Time (weeks) 1 2 3 4 15.0 12.5 10.0 7.5 5.0 * 2.5 0 0 1 2 3 4 5 Time (weeks) Professor Richard Pestell, PhD, MD www.cytodyn.com 1 17 7 Control MaravirocCCR5 Antagonists Block Breast Cancer Metastasis Time (weeks) 1 2 3 4 15.0 12.5 10.0 7.5 5.0 * 2.5 0 0 1 2 3 4 5 Time (weeks) Professor Richard Pestell, PhD, MD www.cytodyn.com 1 17 7 Control Maraviroc

Professor Richard G. Pestell CCR5 Antagonists Block Prostate Cancer Metastasis Professor Richard Pestell, PhD, MD www.cytodyn.com 1 18 8 Control MaravirocProfessor Richard G. Pestell CCR5 Antagonists Block Prostate Cancer Metastasis Professor Richard Pestell, PhD, MD www.cytodyn.com 1 18 8 Control Maraviroc

Objective Tumor Response, Phase 1 Trial advanced-stage metastatic colorectal cancer who are refractory to standard chemotherapy, including regorafenib Partial Response (RECIST) Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients Cancer Cell. 2016 587-601 2 21 1Objective Tumor Response, Phase 1 Trial advanced-stage metastatic colorectal cancer who are refractory to standard chemotherapy, including regorafenib Partial Response (RECIST) Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients Cancer Cell. 2016 587-601 2 21 1

Leronlimab (PRO 140) Breast Cancer Study PRO 140 525mg 1sc/week Carboplatin AUC 2q week x3 28 days cycle Endpoints 1. OS 2. PFS’ 3. Decreased CTC Breakthrough (unmet need) November 2018-March 2019 April 2019-July 2021 (Phase III) Phase II 2 22 2 TNBC Rx Refractory CCR5+ CTCLeronlimab (PRO 140) Breast Cancer Study PRO 140 525mg 1sc/week Carboplatin AUC 2q week x3 28 days cycle Endpoints 1. OS 2. PFS’ 3. Decreased CTC Breakthrough (unmet need) November 2018-March 2019 April 2019-July 2021 (Phase III) Phase II 2 22 2 TNBC Rx Refractory CCR5+ CTC

Potential Market Size for CCR5 Antagonist for Breast Cancer Trastuzumab for breast cancer with HER-2+ patients Annual sales = $15 billion HER-2+ is about 12% of breast cancer population CCR5 + is about 50% breast cancer population Market potential ~ 4 x $15 billion = $60 billion Daniel Lindner, M.D., Ph.D. – Cleveland Clinic www.cytodyn.com 1 19 9Potential Market Size for CCR5 Antagonist for Breast Cancer Trastuzumab for breast cancer with HER-2+ patients Annual sales = $15 billion HER-2+ is about 12% of breast cancer population CCR5 + is about 50% breast cancer population Market potential ~ 4 x $15 billion = $60 billion Daniel Lindner, M.D., Ph.D. – Cleveland Clinic www.cytodyn.com 1 19 9

Other Potential Non-Dilutive Capital Raise Ø Prognostic Test Potential licensing in 2019 Ø Potential use of leronlimab • Already sent product to interested EU collaborators • Already testing for CCR5 staining purposes Ø Several abstracts • At least 5 abstract are ready or will be submitted for publishing in 2019 • Presenting in many Prostate and other oncology conferences in 2019 www.cytodyn.com 1 19 9Other Potential Non-Dilutive Capital Raise Ø Prognostic Test Potential licensing in 2019 Ø Potential use of leronlimab • Already sent product to interested EU collaborators • Already testing for CCR5 staining purposes Ø Several abstracts • At least 5 abstract are ready or will be submitted for publishing in 2019 • Presenting in many Prostate and other oncology conferences in 2019 www.cytodyn.com 1 19 9

PRO 140 Important Milestones for HIV and Cancer 2019 Milestones Target Dates BLA submission 1H2019 Revenue potential of about $480 million 2020 Large Pharma discussion for potential licensing or partnering 1H2019 Triple Negative Breast Cancer study first patient injected 1Q2019 Triple Negative Breast Cancer study Interim results 1H2019 Late Breaker at CROI – Combination therapy – Monotherapy Will apply Prognostic test licensed 2019 IND-Protocol for colon cancer Phase 2 1H2019 www.cytodyn.com 2 24 4PRO 140 Important Milestones for HIV and Cancer 2019 Milestones Target Dates BLA submission 1H2019 Revenue potential of about $480 million 2020 Large Pharma discussion for potential licensing or partnering 1H2019 Triple Negative Breast Cancer study first patient injected 1Q2019 Triple Negative Breast Cancer study Interim results 1H2019 Late Breaker at CROI – Combination therapy – Monotherapy Will apply Prognostic test licensed 2019 IND-Protocol for colon cancer Phase 2 1H2019 www.cytodyn.com 2 24 4